BHSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOHARVEST SCIENCES INC.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.80−0.05 (-2.70%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
BIOHARVEST SCIENCES INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Total | $34.51M | $25.19M | $12.67M | 100.0% | +37.0% |
| Entity-wide | $34.51M | $25.19M | $12.67M | 100.0% | +37.0% |
| Products | $32.63M | $24.91M | $12.67M | 94.6% | +31.0% |
| North America | $30.59M | $23.01M | $10.86M | 88.6% | +32.9% |
| Israel | $3.92M | $2.18M | $1.81M | 11.4% | +80.2% |
| CDMO Services | $1.88M | $282.00K | $0 | 5.4% | +566.0% |
By product or service
By region
From the segment and revenue-disaggregation notes of Bioharvest Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.